Recent advances in autoimmune autonomic ganglionopathy

Nicole Winston, Steven Vernino

Research output: Contribution to journalReview article

31 Scopus citations

Abstract

Purpose of review: This review highlights recent advances in our understanding of autoimmune autonomic ganglionopathy (AAG) including serological diagnosis, clinical observations, pathophysiology, and treatment. Recent findings: Classical AAG is a subacute disorder associated with antibodies against ganglionic acetylcholine receptors. Recent observations demonstrate that these antibodies cause a specific inhibition of synaptic transmission in autonomic ganglia and antibody levels correlate in a predictable way with severity of autonomic failure. Ganglionic acetylcholine receptor antibodies can be associated with other neurological disorders including chronic or restricted forms of autonomic dysfunction and with neurological or paraneoplastic disorders unrelated to the autonomic nervous system. Treatment of AAG is based on case reports. It is clear that AAG patients respond to immunomodulatory treatments but combination immunotherapy may be required to achieve a clinical response. Recently, additional clinical observations indicate that AAG patients may also show signs of treatment-responsive cognitive impairment. Summary: The pathophysiology and varied clinical presentation of AAG are becoming more clear. AAG is a treatable antibody-mediated disorder of autonomic ganglionic synaptic transmission. Future studies will continue to define the optimal diagnostic and therapeutic approach to autoimmune autonomic disorders.

Original languageEnglish (US)
Pages (from-to)514-518
Number of pages5
JournalCurrent Opinion in Neurology
Volume23
Issue number5
DOIs
StatePublished - Oct 1 2010

    Fingerprint

Keywords

  • acetylcholine receptor
  • antibodies
  • orthostatic hypotension
  • synaptic transmission

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this